A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.
The Department of Energy’s Center for Bioenergy Innovation, led by Oak Ridge National Laboratory, recently added three new members to its board of directors: Deborah Crawford of the University of Tennessee, Knoxville; Susan Hubbard of ORNL; and Maureen McCann of the National Renewable Energy Laboratory.
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
Five technologies invented by scientists at the Department of Energy’s Oak Ridge National Laboratory have been selected for targeted investment through ORNL’s Technology Innovation Program.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
Tackling the climate crisis and achieving an equitable clean energy future are among the biggest challenges of our time.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
ORNL and Tuskegee University have formed a partnership to develop new biodegradable materials for use in buildings, transportation and biomedical applications.
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.